Julie R. Brahmer

Bloomberg (United States) — United States

Medicine · Health Sciences

115h-index121.8kcitations822works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(400), Lung Cancer Treatments and Mutations(341), Cancer Genomics and Diagnostics(176), Colorectal Cancer Treatments and Studies(132), Lung Cancer Research Studies(120)

Publications820 total

Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical utility study
2026Open Access
127 Pembrolizumab Monotherapy for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (NSCLC): 10-Year Outcomes From Clinical Trials
Lung Cancer·2026
Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis
The Journal of Rheumatology·2026Open Access
Figure S2 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025Open Access
Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
2025Open Access
97 Statistical and systematic uncertainties affect biomarker reliability: a case study in multiplex immunofluorescence
Regular and Young Investigator Award Abstracts·2025Open Access
1065 The role of a tertiary immunotherapy clinic in facilitating immunotherapy related toxicity management in the community
Regular and Young Investigator Award Abstracts·2025Open Access
1040 Racial differences in peripheral cytokine signature do not lead to differences in immunotherapy outcome or toxicity
Regular and Young Investigator Award Abstracts·2025Open Access
1046 Autoimmune risk alleles do not contraindicate immune checkpoint inhibitor use: findings from a prospective pan-tumor cohort
Regular and Young Investigator Award Abstracts·2025Open Access
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor Pneumonitis
American Journal of Respiratory Cell and Molecular Biology·2025· 2 cited
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability
2025Open Access
Supplemental Table 3 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
Supplemental Table 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
Data from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
Confidence in patient-provider consideration of immunotherapy in a congested landscape.
JCO Oncology Practice·2025
Supplemental Table 6 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure 1 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
Supplemental Figure 2 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
Supplemental Table 4 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
Figure 3 from Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
2025Open Access
page 1 of 41Next →

Frequent Co-authors

Scott Antonia(12), Drew M. Pardoll(12), Matthew D. Hellmann(12), Suzanne L. Topalian(11), Scott Gettinger(11), David R. Spigel(11), Jeffrey A. Sosman(9), Jarushka Naidoo(9), Janis M. Taube(8), Neal Ready(8), Hossein Borghaei(8), Patrick M. Forde(8), John D. Powderly(7), Leora Horn(7), Laura Q.M. Chow(7), William J. Geese(7), Kristen A. Marrone(7), F. Stephen Hodi(6), David C. Smith(6), David F. McDermott(6)